Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

169.20 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Jul 16, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 4,070
Open 169.20
Bid (Size) 168.50 (1)
Ask (Size) 169.18 (3)
Prev. Close 169.20
Today's Range 169.20 - 169.20
52wk Range 134.56 - 182.89
Shares Outstanding N/A
Dividend Yield 3.50%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 High-Yield Dividend Stocks Beating Inflation
High-yield dividend stocks are one of the surest paths to beating inflation as the cost of everything remains high in mid-2024. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
3 Quantum AI Stocks That Could Redefine Computing
Three quantum AI stocks could shape the future of computing, which means current market prices are very cheap. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence

Performance

YTD
+5.87%
+5.87%
1 Month
-0.28%
-0.28%
3 Month
+4.10%
+4.10%
6 Month
+4.78%
+4.78%
1 Year
+25.49%
+25.49%

More News

Read More
7 Recession-Proof Stocks to Shield Your Portfolio in 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
3 Spinoff Stocks You Should Buy Now: July 2024
Via InvestorPlace
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
Via The Motley Fool
AbbVie Unusual Options Activity
Via Benzinga
$1000 Invested In AbbVie 10 Years Ago Would Be Worth This Much Today
Via Benzinga
A Closer Look at AbbVie's Options Market Dynamics
Via Benzinga
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
3 High-Yield Dividend Stocks That Still Look Like Bargains
Via The Motley Fool
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
Via Benzinga
Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US
Via Benzinga
Topics Cannabis
Exposures Cannabis
A Glimpse Into The Expert Outlook On AbbVie Through 7 Analysts
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
Via MarketBeat
The 7 Best Warren Buffett Stocks to Buy in July 2024
Via InvestorPlace
Healthcare Stocks Continue To Lag The Market-Can Anything Help ?
Via Talk Markets
The Smartest Dividend Stocks to Buy With $250 Right Now
Via The Motley Fool
EXCLUSIVE: GLP-1 Weight-Loss Drugs Could Become A Trillion-Dollar Market, Predicts Tema ETFs CEO
Via Benzinga
Topics ETFs
MarketBeat Week in Review – 7/1 - 7/5
Via MarketBeat
Topics Economy
Exposures Interest Rates
AbbVie Stock: A Perfect Dip for Investors to Buy
Via MarketBeat
Topics ETFs
New Golden Investment: Universal Health Realty Income Trust
Via Talk Markets
7 Dividend Aristocrats That Will Have Investors in High-Yield Heaven
Via InvestorPlace
Topics Stocks
Exposures US Equities
3 Under-the-Radar Biotech Stocks With Blockbuster Potential
Via InvestorPlace
3 Retirement All-Stars for Steady Growth and Income
Via InvestorPlace
Topics Retirement
Exposures Pension
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.